AMGN Jun 2024 160.000 put
| Previous close | 0.2400 |
| Open | 0.2400 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 160.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.2400 - 0.2400 |
| Contract range | N/A |
| Volume | |
| Open interest | 504 |
- Yahoo Finance Video
Amgen, DraftKings, Live Nation: Trending tickers
Shares of Amgen (AMGN) are soaring at Thursday's market close after reporting first quarter results, with revenue exceeding expectations. The biotechnology giant's revenue rose by 22% during the quarter. DraftKings (DKNG) also delivered a strong earnings report, surpassing analysts' estimates on both the top and bottom lines. Buoyed by this performance, the company raised its full-year outlook. Live Nation (LYV) topped revenue estimates in its first quarter earnings, although the company reported a loss of $0.53 per share. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith
BloombergAmgen Soars as CEO Touts Experimental Obesity Drug’s Progress
(Bloomberg) -- Amgen Inc.’s shares soared after its chief executive officer said he was “very encouraged” by early results from a study of the company’s experimental obesity drug, MariTide. Most Read from BloombergSaudi Arabia Steps Up Arrests Of Those Attacking Israel OnlineApple Rallies on Upbeat Forecast, Record-Setting BuybackTurkey Confirms All Trade Halt With Israel Over War in GazaHuawei Secretly Backs US Research, Awarding Millions in PrizesTrump Auditions VP Picks Before Wealthy Donors
Barrons.comAmgen Stock Jumps on Obesity Drug Optimism. What Comes Next.
The company is trying to carve a niche in a rapidly growing obesity-drug market that’s currently dominated by Eli Lilly and Novo Nordisk.
